A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors

This publication has 26 references indexed in Scilit:

• Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
  Journal of Clinical Oncology, 2020
• Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients
  Thoracic Cancer, 2020
• The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
  Nature, 2019
• The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience
  Cancer Genomics & Proteomics, 2019
• Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2018
• Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
  Journal of Clinical Oncology, 2018
• Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2018
• First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2017
• Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2016
• Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?
  Genes & Cancer, 2012